Alexion adds a failed pivotal Soliris trial to an air of crisis. The perfect time to talk buyout
With its executive suite in turmoil and the company in crisis over an unexplained fraud probe, Alexion $ALXN reported today that its Phase II/III registration study for Soliris for a serious complication linked to organ transplants has failed.
Investigators were hoping to make a case for the expanded use of Soliris in treating delayed graft function (DGF) after kidney transplantation in adult recipients of a deceased donor kidney has failed. But in looking at a primary endpoint that eyed the drug’s impact on the need for dialysis as well as death, graft loss, and loss to follow-up, including discontinuation, the drug flopped against the placebo arm.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.